INTELLIA THERAPEUTICS INC (NTLA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NTLA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NTLA | ["Biopharma Industry Experience","Executive Leadership"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CYTK | 63 | [] | ["Audit Committee","Compliance Committee"] | 2026 | |
| VCYT | Founder and President; Member | 63 | ["Founder and President of Tiba Global Access LLC","Over 34-year tenure at Merck in senior leadership roles","Experience in strategic roles in the biopharmaceutical industry","Director on the board of numerous companies","Bachelor of Pharmacy degree from Rutgers School of Pharmacy","M.B.A. from St. Joseph’s University","Senior Leadership","Diagnostics","Biopharma","U.S. Healthcare Reimbursement","Global Enterprise","Accounting and Auditing (including Sustainability Reporting)","Public Board","Technology, Innovation and AI","Cybersecurity","Regulatory and Risk Oversight","Commercialization and Market Access","Sales and Marketing"] | ["Nominating and Corporate Governance","Regulatory and Compliance","Regulatory and Compliance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Ms. Bhanji served on the audit committee throughout 2025. Ms. Bhanji is independent for audit committee purposes as that term is defined in the applicable rules of the SEC and Nasdaq. Ms. Bhanji served on the compensation committee throughout 2025. Ms. Bhanji is independent as defined in the applicable SEC and Nasdaq rules. Ms. Bhanji was a member of the science and technology committee throughout 2025.